02186.HK
Luye Pharma Group Ltd.
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 1.59
+0.96%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 12.3B | 6.3B | 6.1B | 6.1B | 6.0B |
| Cost of Revenue | 4.3B | 2.1B | 2.0B | 1.9B | 1.8B |
| Gross Profit | 8.0B | 4.2B | 4.0B | 4.2B | 4.1B |
| Operating Expenses | |||||
| R&D Expense | 884.9M | 413.9M | 498.6M | 586.2M | 857.3M |
| SG&A Expense | 4.9B | 2.5B | 2.4B | 2.7B | 2.4B |
| General & Admin Expense | 1.3B | 679.6M | 582.0M | 644.0M | 582.9M |
| Selling & Marketing Expense | 3.6B | 1.8B | 1.8B | 2.1B | 1.8B |
| Other Expenses | 3.5M | — | — | — | — |
| Total Operating Expenses | 5.8B | 2.9B | 2.9B | 3.3B | 3.3B |
| Cost and Expenses | 10.0B | 5.1B | 4.9B | 5.2B | 5.1B |
| Operating Income (EBIT) | 2.3B | 1.2B | 1.1B | 917.9M | 880.6M |
| Non-Operating | |||||
| Interest Income | 44.2M | 96.1M | 84.4M | 117.1M | 88.7M |
| Interest Expense | 1.2B | 686.6M | 561.8M | 675.5M | 471.8M |
| Net Interest Income | (1.2B) | (590.5M) | (477.4M) | (558.3M) | (383.1M) |
| Other Non-Op Income/Expense | (483.4M) | (298.2M) | (308.0M) | (217.8M) | (210.9M) |
| Non-Operating Income (excl Interest) | 179.9M | 25.2M | 19.1M | (346.8M) | 91.5M |
| EBT (Pre-Tax Income) | 1.8B | 944.6M | 839.2M | 700.1M | 669.8M |
| Income Tax Expense | 476.0M | 239.0M | 194.2M | 161.0M | 86.5M |
| Bottom Line | |||||
| Net Income | 1.1B | 618.7M | 471.9M | 532.6M | 604.8M |
| Earnings from Cont. Ops | 1.3B | 705.7M | 645.0M | 539.1M | 583.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.1B | 618.7M | 471.9M | 532.6M | 604.8M |
| Per Share | |||||
| Basic EPS | HK$0.28 | HK$0.16 | HK$0.13 | HK$0.14 | HK$0.17 |
| Diluted EPS | HK$0.28 | HK$0.16 | HK$0.13 | HK$0.14 | HK$0.17 |
| Revenue Per Share | HK$3.08 | HK$1.62 | HK$1.61 | HK$1.65 | HK$1.72 |
| Shares | |||||
| Basic Shares Outstanding | 4.0B | 3.9B | 3.8B | 3.7B | 3.5B |
| Diluted Shares Outstanding | 4.0B | 3.9B | 3.8B | 3.7B | 3.5B |
| Profitability Metrics | |||||
| EBITDA | 3.8B | 2.1B | 1.9B | 2.1B | 1.8B |
| D&A | 1.7B | 839.5M | 790.7M | 701.9M | 671.3M |
| EBIT | 2.1B | 1.2B | 1.1B | 1.4B | 1.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026